View the PDF of this article at: https://www.the-jci.org/press/17202.pdf

Key to blocking assembly of hepatitis delta virus highlights potential new treatment

Jeffrey Glenn and colleagues at Stanford University in California have developed a small animal model for hepatitis delta virus (HDV) which confirms that inhibitors of prenylation a vital step in virus assembly within host cells are capable of blocking this assembly and facilitating viral clearance. The study highlights their potential relevance for the treatment of chronic delta hepatitis.

In the accompanying commentary, Drs. Theo Heller and Jay Hoofnagle from the National Institutes of Health in Bethesda, Maryland, discuss the different stages of HDV replication within host cells and how this most recent finding can be used to develop suitable therapies for HDV.

TITLE: In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus

AUTHOR CONTACT:
Jeffrey Glenn
Stanford University School of Medicine, Palo Alto, California, USA.
Phone: 650-725-3373
Fax: 650-723-5488
E-mail: jeffrey.glenn@stanford.edu

View the PDF of this article at: https://www.the-jci.org/press/17704.pdf

ACCOMPANYING COMMENTARY:
Denying the wolf access to sheep's clothing

AUTHOR CONTACT:
Jay H. Hoofnagle
National Institutes of Health, Bethesda, Maryland, USA.
Phone: 301-496-1333
Fax: 301-480-7926
Email: hoofnaglej@extra.niddk.nih.gov

View the PDF of this commentary at: https://www.the-jci.org/press/19417.pdf

IL-13 and adenosine: partners in the molecular dance we call asthma
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-Aug-2003